Targeted Radionuclide Therapy Articles


  • Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.

    Targeted radionuclide therapy using (177) Lu-labeled peptidomimetic inhibitor of prostate specific membrane antigen (PSMA) viz. PSMA-617 is emerging as one the most effective strategies for management of metastatic prostate cancer, which is one of the leading causes of cancer related death.

    Published June 13, 2016
  • Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.

    Because of the broad incidence, morbidity and mortality associated with prostate-derived cancer, the development of more effective new technologies continues to be an important goal for the accurate detection and treatment of localized prostate cancer, lymphatic involvement and metastases.

    Published September 7, 2016
  • TAT-10: Session IV: Nanocarriers

    Kanazawa, Japan ( There is a substantial problem with binding the radioisotope to a molecular structure. Isotopes like Ra223 and Ac225 have decay chains that emit a total of four alphas. When the first decay occurs, the recoil of the daughter nucleus is sometimes sufficient to break the molecular bond holding the radioisotope. For the isotopes above, one of the daughter nuclei has a long enough half-life to travel through the body. This is doubly bad since not only is the alpha lost to the tumor site but the free isotope may damage healthy organs, especially the liver and kidneys.
    Published June 21, 2017